Drug intelligence / Profile preview

LAVA-206 + LAVA-207

Development stage: Unknown
Lead developer: LAVA Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LAVA-206 + LAVA-207 is a bispecific gamma delta T-cell engager from LAVA Therapeutics targeting **PSMA** (prostate-specific membrane antigen) on tumor cells and the TCR of Vγ9Vδ2 T cells to conditionally activate these effector cells for potent tumor killing. Developed using the company's Gammabody platform, it aims to treat **castration-resistant prostate cancer** with a favorable safety profile by leveraging the innate-like properties of gamma delta T cells. It represents an early-stage immunotherapy candidate in preclinical or Phase 1 development.[9]

Targets

TRDV2 (T cell receptor delta variable 2)PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on LAVA-206 + LAVA-207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAVA-206 + LAVA-207.

Explore the full profile